10x GenomicsTXG -0.86%62 3-Year ROIIC % is -135.75 as of Dec. 2025. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $18.94 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 621 Healthcare Providers & Services companies, 10x Genomics ranks worse than 90.82% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
10x Genomics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -135.75%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for 10x Genomics's 3-Year ROIIC % or its related term are showing as below:
TXG's 3-Year ROIIC % is ranked worse than 90.82% of 621
companies
in the Healthcare Providers & Services industry
Industry Median: 3.46
vs TXG: -135.75
10x Genomics (NAS:TXG) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
10x Genomics 3-Year ROIIC % Related Terms
10x Genomics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for 10x Genomics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where 10x Genomics's 3-Year ROIIC % falls into.
10x Genomics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -110.885 (Dec. 2025) - -167.944 (Dec. 2022) )
/
( 472.652 (Dec. 2025) - 514.683 (Dec. 2022) )
=
57.059
/
-42.031
=
-135.75%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
10x Genomics (TXG) has a 3-Year ROIIC % of -135.75 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #564 out of 621 companies in the Healthcare Providers & Services industry, placing it in the top 90.8%.
Is 10x Genomics' 3-Year ROIIC % too high?
10x Genomics' current 3-Year ROIIC % is -135.75. Based on the distribution chart, 10x Genomics ranks #564 out of 621 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' 3-Year ROIIC % compare to DOCS and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #564 out of 621 companies for 3-Year ROIIC %. This places 10x Genomics in the lower half of its industry. The industry median 3-Year ROIIC % is 3.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.46, based on 621 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current 3-Year ROIIC % is -135.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.94, compared to a current price of $42.75 — trading 125.7% above its estimated fair value. The current 3-Year ROIIC % is -135.75. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For 10x Genomics (TXG), the current 3-Year ROIIC % is -135.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $42.75 is trading 125.7% above its estimated GF Value™ of $18.94.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
3-Year ROIIC %: -135.75
GF Value™: $18.94 vs. price of $42.75 (125.7% above fair value)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score
Get the complete analysis for TXG
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
